Organisation for Economic Co-Operation and Development
HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets
most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries